Evidence map›Paper›PMID 35008882›Full record

ArticleInternational journal of molecular sciences2021

Vypal2: A Versatile Peptide Ligase for Precision Tailoring of Proteins.

Dingpeng Zhang, Zhen Wang, Side Hu, Julien Lescar, James P Tam, Chuan-Fa Liu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. The crosstalk between iron metabolism and immune tolerance in autoimmunity.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dingpeng ZhangSchool of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore.ORCID 0000-0001-9652-0067
Zhen WangSchool of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore.
Side HuSchool of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore.ORCID 0000-0001-9320-5360
Julien LescarSchool of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore.
James P TamSchool of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore.ORCID 0000-0003-4433-198X
Chuan-Fa LiuSchool of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore.

Funding

Ministry of Education MOE2016-T3-1-003; 2019-T1-002-100
6 · The paper itself

Abstract

The last two decades have seen an increasing demand for new protein-modification methods from the biotech industry and biomedical research communities. Owing to their mild aqueous reaction conditions, enzymatic methods based on the use of peptide ligases are particularly desirable. In this regard, the recently discovered peptidyl Asx-specific ligases (PALs) have emerged as powerful biotechnological tools in recent years. However, as a new class of peptide ligases, their scope and application remain underexplored. Herein, we report the use of a new PAL, VyPAL2, for a diverse range of protein modifications. We successfully showed that VyPAL2 was an efficient biocatalyst for protein labelling, inter-protein ligation, and protein cyclization. The labelled or cyclized protein ligands remained functionally active in binding to their target receptors. We also demonstrated on-cell labelling of protein ligands pre-bound to cellular receptors and cell-surface engineering via modifying a covalently anchored peptide substrate pre-installed on cell-surface glycans. Together, these examples firmly establish Asx-specific ligases, such as VyPAL2, as the biocatalysts of the future for site-specific protein modification, with a myriad of applications in basic research and drug discovery.

Indexed as

LigasesBiotechnologyHumansMCF-7 CellsProtein Processing, Post-TranslationalProteinsLigasesProteinsbiocatalystscell surface labelingprotein cyclizationprotein labelingVyPAL2

Identifiers

PMID35008882
PMCPMC8745061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.